Skip to content

NAC +taVNS in IDM Who Are Poor Oral Feeders

N-acetylcysteine Plus Transcutaneous Vagus Nerve Stimulation in Infants of Diabetic Mothers Who Fail Oral Feeding

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04632069
Enrollment
10
Registered
2020-11-17
Start date
2021-08-12
Completion date
2024-07-01
Last updated
2024-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Feeding Disorders, Infant of Diabetic Mother, Oxidative Stress, Vagus Nerve Stimulation

Brief summary

Infants of diabetic mothers who are failing to learn oral feeding by term age equivalence have greater CNS oxidative stress, which interact to predict poor neuroplasticity response to transcutaneous vagus nerve stimulation paired with oral feeding. We propose treating the oxidative stress in IDM infants prior to initiating taVNS, with an FDA-approved antioxidant (N-acetylcysteine, NAC) to improve CNS oxidative stress, which in turn regulates expression of many genes including BDNF, that may enhance motor learning.

Detailed description

Our group has recently conducted a first-in-infants pilot trial of pairing transcutaneous auricular vagus nerve stimulation (taVNS) with feeding to assist learning oromotor skills. We are enrolling preterm and HIE infants who are failing to learn oral feeds and clinically determined to need a G-tube. In preliminary data, taVNS paired with one or two daily feedings for 2 weeks resulted in 50% of infants attaining full feeds and avoiding G-tube. A notable number of non-responders were infants of diabetic mothers (IDM) exposed to poor glucose control during pregnancy, all of whom required a G-tube. Uncontrolled maternal hyperglycemia is associated with increased systemic and neuro-inflammation, CNS oxidative stress, DNA damage, and worse neonatal outcomes compared to infants of euglycemic mothers. In neonatal animal models, hyperglycemia has been shown to decrease BDNF, alter long-term synaptogenesis and hippocampal neurochemistry, with ongoing CNS oxidative stress and inhibition of the cortical neuronal plasticity required for learning. In our pilot trial of taVNS-paired feeding, CNS glutathione concentrations (GSH), a MR spectroscopy (MRS) marker of oxidative stress, had significant interaction with IDM in predicting outcome, strongly suggesting that ongoing CNS oxidative stress contributes to neuropathology in IDMs failing oral feeding. NAC is an FDA-approved antioxidant that is safe and crosses the blood brain barrier, increasing CNS GSH. NAC reduces CNS oxidative stress, enhances learning and provides a neuroprotective effect after brain injury in our and others neonatal HI and neuroinflammatory animal models. Both GSH and BDNF enhance neuroplasticity. Therefore, we hypothesize that pre-treatment with NAC in IDMs who are failing oral feeding, followed by taVNS-paired feeding, will decrease oxidative stress induced by maternal hyperglycemia and IDM-associated brain injury, and increase response to taVNS-paired feeding rehabilitation.

Interventions

COMBINATION_PRODUCTN acetyl cysteine + vagus nerve stimulation

NAC x 14 days, taVNS x 10 days

Sponsors

National Institute of General Medical Sciences (NIGMS)
CollaboratorNIH
Medical University of South Carolina
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Masking description

Co-investigator analyzing MRI data will be blinded to timing of MRI scan and dose

Intervention model description

We will obtain parental consent, and then administer NAC 100mg/kg loading dose, followed by 75mg/kg q 6h via nasogastric tube, started 4 days prior to taVNS-paired feeding and continued for a total of 14 days. We will perform pharmacokinetics of oral NAC, and MRIs prior to, after 3-4 days of NAC, and after taVNS treatment period.

Eligibility

Sex/Gender
ALL
Age
3 Weeks to 5 Months
Healthy volunteers
No

Inclusion criteria

* Infants of diabetic mothers who are failing oral feeding, \>39weeks gestation at enrollment, who are clinically stable, on minimal respiratory support (nasal cannula or room air), and clinical team has determined are G-tube candidates

Exclusion criteria

* Unstable infants or those requiring positive pressure respiratory support * Infants \<39 weeks gestation at enrollment * Major unrepaired congenital anomalies or anomalies that limit feeding volumes * Infants with cardiomyopathy * Repeated episodes of autonomic instability (apnea/ bradycardia) not self resolving

Design outcomes

Primary

MeasureTime frameDescription
Daily Oral Feeding Volumes : Difference in Mean IncreaseDay -14 to 0, Day 1 to 18Difference in the Mean daily change in oral feeding volume(reported in in ml/kg/d) from Day 1-18 days of NAC+taVNS treatment minus Days -14 to 0 (baseline)

Secondary

MeasureTime frameDescription
Metabolite Concentrations in Basal Gangliabaseline to 4 daysChange in \[GSH\] by MRS from baseline to day 4 of NAC

Countries

United States

Participant flow

Recruitment details

Recruitment from 8.12.21 to 3.1.23 in the Neonatal intensive care unit of the Medical University of South Carolina

Participants by arm

ArmCount
NAC + taVNS
NAC will be given via nasogastric tube (n,g.) 75mg/kg/dose or 100mg/kg n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 14 days. N acetyl cysteine + vagus nerve stimulation: NAC x 14 days, taVNS x 14days
10
Total10

Baseline characteristics

CharacteristicNAC + taVNS
Age, Continuous41.1 weeks post menstrual age
STANDARD_DEVIATION 1.1
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
mean daily oral feeding volume of formula or breast milk47 ml/kg/day
STANDARD_DEVIATION 29
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
3 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
5 Participants
Region of Enrollment
United States
10 participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
1 / 10
other
Total, other adverse events
2 / 10
serious
Total, serious adverse events
0 / 10

Outcome results

Primary

Daily Oral Feeding Volumes : Difference in Mean Increase

Difference in the Mean daily change in oral feeding volume(reported in in ml/kg/d) from Day 1-18 days of NAC+taVNS treatment minus Days -14 to 0 (baseline)

Time frame: Day -14 to 0, Day 1 to 18

Population: infants of diabetic mothers failing oral feeds in G-tube discussions

ArmMeasureValue (MEAN)Dispersion
NAC + taVNSDaily Oral Feeding Volumes : Difference in Mean Increase2.1 ml/kg/day po daily changeStandard Deviation 0.4
Comparison: Daily change in po feeding volumes expressed as po ml/kg/d \[reported as the mean daily change from Day 1 to 18 during NAC/NAC+taVNS minus baseline mean daily change Day -14 to day 0 (before treatment)\] Null hypothesis: there will be no significant difference in daily change in po feeding volume (ml/kg/d) from baseline to during treatment Power analysis: Estimated +0.2 ml/kg/d before taVNS, and +3ml/kg/d during the 18days of NAC+taVNS treatment, requiring 10 infants with power of 80%, a=0.05.p-value: 0.009Regression, Linear
Secondary

Metabolite Concentrations in Basal Ganglia

Change in \[GSH\] by MRS from baseline to day 4 of NAC

Time frame: baseline to 4 days

Population: participants with adequate MRS spectra for analysis

ArmMeasureValue (MEAN)Dispersion
NAC + taVNSMetabolite Concentrations in Basal Ganglia0.13 mMStandard Deviation 0.08
Comparison: \[GSH\] at baseline compared with \[GSH\] at day 4 of NAC- by paired t-test in which each participant's \[GSH\] is compared at 2 time points Null hypothesis: the \[GSH\] in the basal ganglia will be no different after Day 4 of NAC than \[GSH\] at baseline Power calculation:With 80% power, alpha of 0.05, we would need 7 patients to show a significant change in basal ganglia \[GSH\] of 0.14 +/- 0.13mM from baseline to Day 4 of NAC (paired t-test).p-value: 0.01t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026